Thermo Fisher Scientific Inc.
TMO Healthcare Diagnostics & Research
Thermo Fisher Scientific Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 billion, up 3.91% from fiscal 2024. In the quarter to June 2026, revenue grew 10.5%, EPS grew 9.35%, free cash flow grew 51.8% and total debt rose 18.7%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.
Follow TMO
Thermo Fisher Scientific Inc. (TMO) EBITDA
Thermo Fisher Scientific Inc.'s EBITDA for fiscal 2025 was $10.5B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $11.1B. Over the past ten years it has ranged from $4.0B (fiscal 2015) to $12.6B (fiscal 2021); the current reading is higher than 82% of that period. Thermo Fisher Scientific Inc. ranks 1st of 52 Diagnostics & Research companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $10.5B | 0.78% |
| FY2024 | $10.4B | 1.76% |
| FY2023 | $10.3B | (12.82%) |
| FY2022 | $11.8B | (6.70%) |
| FY2021 | $12.6B | 24.72% |
| FY2020 | $10.1B | 47.27% |
| FY2019 | $6.9B | 13.57% |
| FY2018 | $6.1B | 21.17% |
| FY2017 | $5.0B | 18.43% |
| FY2016 | $4.2B | 4.77% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $2.9B | 11.69% |
| Mar 2026 | $2.6B | (12.84%) |
| Dec 2025 | $3.0B | 14.69% |
| Sep 2025 | $2.6B | 3.17% |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| TMO Thermo Fisher Scientific Inc. | $11.1B |
| DHR Danaher Corporation compare | $7.7B |
| IQV IQVIA Holdings Inc. compare | $3.4B |
| A Agilent Technologies, Inc. compare | $1.9B |
| IDXX IDEXX Laboratories, Inc. compare | $1.6B |
| MTD Mettler-Toledo International, Inc. compare | $1.3B |
| ILMN Illumina, Inc. compare | $1.2B |
| WAT Waters Corporation compare | $942.8M |
| NTRA Natera, Inc. compare | −$223.9M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on TMO
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement